Central and East European Oncology Group

  • Members
    Members

    CEEOG has greatly expanded and now includes 35 academic andcommunity hospitals from Poland, Romania, Slovakia, Bulgaria, Slovenia, Croatia, Bosnia and Hercegovina, Yugoslavia, Hungary, Czech Republic and Russia.

     

     

     

Polish Brain Metastasis Consortium

pbmc-logo

The group was founded in 2005 by Dr. Renata Duchnowska from the Military Medical Institute in Warsaw as a result of establishing an informal network of some Polish oncology centers. A year later group teamed up with foreign research groups and academic centers. In 2008, the patronage of the Group's research covered the CEEOG.

Projects

Ongoing projects

An open label phase II study evaluating the effectiveness of first line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients selected by positive FISH EGFR test (FLIKER), investigator-initiated study, educational grant from Roche Polska sp. z o.o.  Read more »Ongoing projects focus on establishing prognostic and predictive value of selected biomarkers for targeted therapies of lung cancer. Over last five years, we have exchanged assay protocols for immunohistochemistry and gene copy number assessments with particular focus on the following pathways: epidermal growth factor pathway, insulin-like growth factor and MET signaling. The assays were elaborated by both groups to be ready for prospective testing in clinical trials, including ongoing FLIKER study,  in collaboration with the University of Colorado Cancer Center
Retrospective analysis of molecular factors predictive for clinical efficacy of lapatinib in HER2-positive advanced breast cancer patients. Investigator-initiated study, educational grant from GlaxoSmithKleine and Monogram Biosciences. Read more »
Randomised double-blind trial in postmenopausal women with primary breast cancer who have received adjuvant Tamoxifen for 2-3 years, comparing subsequent adjuvant Exemestane treatment with further Tamoxifen Pathology Sub-Study (PathIES), in collaboration with Imperial College of London. Read more »
Randomised double-blind trial in postmenopausal women with primary breast cancer who have received adjuvant Tamoxifen for 2-3 years, comparing subsequent adjuvant Exemestane treatment with further Tamoxifen Pathology Sub-Study (PathIES), in collaboration with Imperial College of London. Read more »
Measurement of HER2-family protein expression and dimerization by Vera Tag assays and association with clinical outcomes in a cohort of women with metastatic breast cancer, in collaboration with Monogram Biosciences.Retrospective analysis of molecular factors predictive for clinical efficacy of lapatinib in HER2-positive advanced breast cancer patient, in collaboration with GlaxoSmithKleine and Monogram BiosciencesMolecular predictors for response and/or resistance to trastuzumab in patients with metastatic breast cancer, in collaboration with Istituto ToscanoMolecular factors associated with brain metastatis in HER2-positive advanced Brest cancer patients, in collaboration with Indiana University and National Cancer Institute, Bethesda

Completed projects

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer, in collaboration with BIG

A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer (SOFT) in collaboration with BIG and IBCSG

CONTACT

Home
 
Medical University of Gdańsk
Department of Oncology and Radiotherapy
7 Dębinki Street
80-211 Gdańsk, Poland 
 
email
Phone: +48 58 349 2282
Fax: +48 58 349 22 44
E-mail: Ten adres pocztowy jest chroniony przed spamowaniem. Aby go zobaczyć, konieczne jest włączenie obsługi JavaScript.